The EU Malaria Fund is a public-private partnership between the European Union, International Organizations, corporations, and organized civic society, providing a novel funding instrument to address market failures in infectious diseases with significant relevance to public health globally.
Continue readingPlasmodium vivax: the Neglected Malaria
Seven Facts about Plasmodium vivax
Continue readingDr. Agustin Arasanz Duque named new Interim CEO of ITSL
As of March 2019, Agustin Arasanz Duque has been named the new interim CEO of ITSL. Dr. Arasanz Duque is a senior consultant manager, with BS in Biology and Business Administration and Management from the University of Barcelona. Co-Founder of Hygeia Technologies S.L. and over 10 years of experience in preparing business plans, IP and regulatory affairs, and scouting new biomedical companies with early stage technologies.
RIS3CAT Project
ITSL participates of a RIS3CAT Project: Noves estratègies per al control del virus de la síndrome respiratori i reproductiu porcí, RIS3CAT – COTPA – Regeva – COMRDDi16-1-0035-01 (2017-2020) co-financed by the European Regional Development Fund (FEDER)
Continue readingNew shareholders
Lorenzo José Fraile y Maria Montoya have recently joined ITSL as a new shareholders
Continue readingITSL at the IPVS & ESPHM 2016 Conference
ITSL at the IPVS & ESPHM 2016 Conference
Continue readingITSL makes a remarkable advance in exosome-based PRRSV vaccine development
Recently, research conducted by the ITSL R&D team have culminated with the publication of a research article in the prestigious journal Veterinary Research (Montaner-Tarbes et al. – 2016)
Continue readingCSO of ITSL Coordinates a National Network of REDiEX
CSO of ITSL Coordinates a National Network of Excellenc in Research and Innovation on Exosomes (REDiEX) funded by MINECO.
Continue readingCSO named President of GEIVEX
CSO named President of the Spaniard Research group on Research and Development on Extracellular Vesicles (GEIVEX)
Continue reading